Cervical cancer starts in the lining of the cervix and is strongly linked to persistent HPV infection. When caught early, it is highly curable.
Globally, cervical cancer is the fourth most common cancer in women, with approximately 660,000 new cases and 350,000 deaths estimated annually. The disease often causes no early symptoms — which is precisely why regular screening is so critical. If you have been diagnosed or have any concerns, seeking medical care as soon as possible is the single most important step you can take.
China accounts for approximately 23% of the world’s cervical cancer cases, with an estimated 150,000 new patients annually. At Fosun Health, this substantial case volume has given our expert teams a depth of experience that ensures precision in every aspect of care — from accurate staging and individualized treatment planning to advanced surgical techniques and multimodal therapy. With thousands of cases treated each year, our protocols are continuously refined by real-world data, delivering better outcomes and quality of life for patients.
Every cervical cancer program has surgery, radiation, and chemotherapy. Here is what makes ours different:
"I am only in my thirties. Can you treat the cancer without taking my womb and my ability to have children?"
The challenge: For women of childbearing age, the diagnosis of cervical cancer brings a devastating double blow: the cancer itself, and the prospect of losing fertility and pelvic organ function. Radical hysterectomy with pelvic lymphadenectomy can damage the hypogastric nerve plexus—leading to urinary retention, constipation, vaginal dryness, and sexual dysfunction. For many young patients, "cure" feels hollow if it means a life without children and a collapsed pelvic floor.
Our answer: Nerve-sparing, fertility-preserving precision surgery tailored to your stage and priorities:
- Fertility-Sparing Radical Trachelectomy: For early-stage (IA2–IB1, tumor ≤2 cm) patients who wish to preserve fertility. We remove the cervix and parametric tissue while preserving the uterine body, ovaries, and fallopian tubes—then reconstruct the uterovaginal junction with a cerclage band to support future pregnancy. Over 70% of patients who attempt pregnancy after this procedure achieve successful live births.
- Nerve-Sparing Radical Hysterectomy: For patients requiring hysterectomy but wishing to protect pelvic floor function. The Da Vinci robot provides 10× magnified 3D vision and tremor-free instruments that trace the pelvic splanchnic nerves and hypogastric plexus with sub-millimeter accuracy—preserving bladder sensation, urinary continence, bowel motility, and sexual function.
- Ovarian Transposition: For patients requiring pelvic radiation, we laparoscopically transpose the ovaries outside the radiation field—protecting hormonal function and preventing premature menopause.
- Sentinel Lymph Node Mapping: Using indocyanine green (ICG) fluorescence guided by the robot, we identify and biopsy only the first-draining lymph nodes—avoiding unnecessary complete lymphadenectomy and reducing lymphedema risk.
What this means for you: "Radical" does not have to mean "destructive." Wherever oncologically safe, we preserve your uterus, your ovaries, your nerves, and your future as a woman.
"My tumor is bleeding heavily, and now my kidney is swollen because the tumor is pressing on the ureter. I am weak and terrified. Can you save me first?"
The challenge: Locally advanced cervical cancer can invade into the paracervical and parametrial tissues, eroding blood vessels and causing torrential vaginal bleeding that soaks through pads within minutes. Simultaneously, tumor or enlarged lymph nodes can compress the ureter—causing hydronephrosis, kidney failure, and unbearable flank pain. Patients are anemic, infected, and too frail for immediate major surgery.
Our answer: A minimally invasive emergency platform that stabilizes you within hours:
- Superselective Internal Iliac Artery Embolization: Through a tiny groin puncture, a microcatheter navigates to the uterine artery, vaginal artery, or internal pudendal branches feeding the tumor. Embolic agents permanently seal the bleeding vessels. Hemorrhage stops immediately. No abdominal incision. No general anesthesia.
- Ureteral Stenting or Percutaneous Nephrostomy: For malignant ureteral obstruction, we place a double-J ureteral stent endoscopically to reopen the blocked channel—or perform percutaneous nephrostomy (PCN) to drain the backed-up urine directly from the kidney, protecting renal function and relieving pain within hours.
- Tumor Hyperthermia: For locally advanced tumors undergoing concurrent chemoradiation, heating the pelvis to 40–43°C sensitizes cancer cells to radiation—a force multiplier that makes the same radiation dose work harder, potentially shrinking the tumor faster to relieve compression on the ureter and blood vessels.
What this means for you: When bleeding won't stop and your kidney is drowning in backed-up urine, our interventional team can stop the hemorrhage, decompress your urinary system, and sensitize the tumor for definitive therapy—all without opening your abdomen.
"My cancer has returned at the vaginal cuff or in the pelvic sidewall lymph nodes. They are talking about removing my bladder and rectum. Is there any other way?"
The challenge: Recurrence in the vaginal vault, parametrium, or pelvic/para-aortic lymph nodes after initial surgery or radiation is one of the most feared scenarios in gynecologic oncology. The standard surgical salvage—total pelvic exenteration—removes the bladder, rectum, and remaining reproductive organs, leaving the patient with permanent urinary and fecal stomas. Many patients are medically unfit for such massive surgery, or simply refuse it.
Our answer: CyberKnife M6 and iodine-125 seed implantation offer curative-intent alternatives without removing a single pelvic organ:
- CyberKnife M6: For isolated vaginal cuff recurrences, pelvic lymph node relapses, or bone/para-aortic oligometastases, 0.1mm sub-millimeter stereotactic radiosurgery tracks tumor motion in real time and converges radiation from thousands of angles. It ablates the recurrence while maximally sparing the bladder, rectum, small bowel, and femoral heads. Completely non-invasive. No stomas. No removal of organs. Curative-intent treatment in 1–5 sessions.
- Iodine-125 Seed Implantation: For recurrent parametrial disease or bulky pelvic lymph nodes, rice-grain-sized radioactive seeds are implanted directly into the tumor under image guidance. They emit continuous internal radiation for 60–180 days—hitting the recurrence from the inside out while surrounding organs receive minimal dose.
- Interventional Arterial Therapy: For localized pelvic recurrence with bleeding, superselective transarterial infusiondelivers drug concentrations 50–100× higher than IV therapy directly to the tumor-feeding branches of the internal iliac artery—shrinking the mass and controlling hemorrhage.
What this means for you: Recurrence does not automatically mean losing your bladder and rectum. Depending on the pattern, we can precision-radiate it, seed it with internal radiation, or starve it through targeted arterial therapy—while every pelvic organ remains exactly where it belongs.
"I have locally advanced cervical cancer. They told me I need weeks of radiation plus chemotherapy. Is there any way to make this work better—and if I progress, what comes next?"
The challenge: Locally advanced cervical cancer (Stage IIB–IIIC) is treated with concurrent chemoradiation—the standard of care globally. Yet some tumors are inherently resistant. When the disease progresses or recurs after primary therapy, options in many regions become limited and costly.
Our answer: We make the standard work harder, and the next line arrive sooner:
- Tumor Hyperthermia as Radiosensitizer: Heating the pelvic tumor to 40–43°C during radiotherapy disrupts DNA repair mechanisms, increases blood flow and oxygenation, and sensitizes cancer cells to both radiation and cisplatin chemotherapy. This force multiplier improves local control rates without increasing radiation dose or toxicity to the bladder and rectum.
- PD-1/PD-L1 Immunotherapy: For persistent, recurrent, or metastatic disease, pembrolizumab combined with chemotherapy ± bevacizumab is approved in China and endorsed by NCCN/CSCO guidelines. For patients who have progressed after primary chemoradiation, this represents a genuine extension of survival.
- China-Original Protocols & Cost Advantage: Novel combination regimens integrating domestic PD-1 inhibitors with anti-angiogenic agents and chemotherapy are in routine clinical use here, often years ahead of availability elsewhere. Developed and manufactured within China's ecosystem, comprehensive treatment costs are 30%–50% of what you would pay in Europe or the US.
Guided by NGS-based molecular profiling and physicians who have managed thousands of cervical cancer cases through multiple lines.
What this means for you: The same radiation and chemotherapy become more lethal to the tumor when paired with hyperthermia. And if the disease advances, your next-line immunotherapy is available here—at a sustainable cost.
When standard therapies reach their limit, we provide rapid access to China's full portfolio of Phase III clinical trials—therapies typically 3–5 years ahead of availability elsewhere. NGS-based molecular matching identifies trials targeting your specific mutation. Every enrollment is ethics-approved with full medical supervision.
Our TCM program runs alongside your primary treatment as a "pelvic vitality and immune optimizer":
Toxicity Reduction: Herbal formulations help protect bone marrow function, ease chemotherapy-induced nausea and vomiting, relieve cancer-related fatigue, and reduce radiation cystitis and proctitis. Specialized protocols address radiation-induced vaginal dryness and stenosis—critical for maintaining quality of life after pelvic radiotherapy.
Efficacy Enhancement: Selected preparations may improve tumor sensitivity to radiation and chemotherapy.
Acupuncture provides additional support for pelvic pain, nausea, fatigue, and postoperative bladder dysfunction. The goal: protect your pelvic organ function, reduce treatment burden, and keep you strong enough to complete every planned cycle—on schedule.
Every cervical cancer case is reviewed by a panel comprising gynecologic oncology surgery, radiation oncology, medical oncology, interventional radiology, urology (for urinary tract involvement), gastroenterology (for rectal involvement), radiology, and pathology specialists. Cervical cancer decisions are uniquely complex: fertility preservation versus radical hysterectomy; nerve-sparing technique selection; neoadjuvant chemotherapy versus upfront surgery versus definitive chemoradiation; and management of post-treatment recurrence without pelvic exenteration.
The MDT convenes within 48 hours of complete documentation. Your plan is a consensus decision optimized for your cancer stage, HPV status, molecular profile, fertility desires, and your life priorities.
Diagnosis:
Stage IIIC1 Squamous Cell Carcinoma of the Cervix
Treatment Plan:
Concurrent chemoradiotherapy combined with intracavitary brachytherapy was administered to avoid surgical trauma. Considering the patient's relatively high risk of recurrence, an immunotherapeutic agent available in China was incorporated concurrently and continued as maintenance therapy following completion of radiotherapy.
Outcome:
The patient demonstrated good immunologic tolerance throughout treatment, with no evidence of disease progression during follow-up. Three months after treatment, PET-CT revealed a marked reduction in tumor burden, approaching complete remission, and biopsy results were negative. No signs of recurrence were observed within one year, and the patient returned to normal work and daily activities.
Led by Dr. Yang Jun, Prof. Luo Pengfei, and Prof. Chen Tao, the Fosun Oncology Center brings together more than 20 world-class medical experts, each with over a decade of extensive oncology experience. Supported by a comprehensive range of advanced therapies — including robotic surgery, precision radiotherapy, minimally invasive intervention, CAR-T cell therapy, and Tumor Treating Fields (TTFields) — the center delivers one-stop, integrated cancer care designed to make treatment more accessible, efficient, and high-quality for every patient.
Key Highlights
- Over 60,000 annual oncology patient admissions across Fosun’s major international hospitals in 2025
More than 17,000 cumulative TACE procedures completed between 2023 and 2025 at Fosun Hospital Guangzhou alone, with international patients accounting for over 10% of total cases
- More than 1,000 successful CyberKnife treatments performed, demonstrating world-class expertise in precision radiotherapy
- A 29.3% five-year survival rate achieved for Glioblastoma Multiforme (GBM) through combined TTFields therapy, representing a significant improvement over the 4.7% baseline
Core Services
- Robotic surgery
- Precision radiotherapy
- Minimally invasive intervention
- CAR-T cell therapy
- Tumor Treating Fields (TTFields)
- Medical oncology
- PET/CT imaging
- Pulmonary nodule diagnosis
- VIP inpatient wards
- Integrated oncology clinics
- Traditional Chinese medicine for oncology
- Cancer screening and early detection
- Genetic testing and counseling
Founded in 1992, Fosun has grown over the past three decades into a global innovation-driven consumer group. In 2007, Fosun International Limited was listed on the Main Board of the Hong Kong Stock Exchange (stock code: 00656.HK). As one of the few Chinese enterprises with strong global operational and investment capabilities, Fosun has developed substantial technological expertise and innovation capacity across multiple industries.
Established in 2010, Shanghai Fosun Health Technology is dedicated to building a world-renowned healthcare group in Asia. Today, the group operates 19 affiliated medical institutions across Foshan, Guangzhou, Shenzhen, Zhuhai, Shanghai, and other major cities, with a total of 6,600 hospital beds and 9 Internet Hospital licenses. Fosun Health ranks No. 1 among China’s private comprehensive medical groups. Its flagship institution, Fosun Foshan Chancheng Hospital, has ranked first among private hospitals in China for eight consecutive years and was honored with the 2026 Global Health Asia-Pacific “Oncological Medical Service Provider of the Year” award.
As the flagship hospital of Fosun Health, Fosun Foshan Chancheng Hospital was founded in 1958. The hospital currently hosts 28 key specialty development programs, including 2 provincial-level, 13 municipal-level, and 13 district-level key specialties. Its services span 22 medical disciplines, including spinal orthopedics, traditional Chinese medicine gynecology, obstetrics and gynecology, cardiovascular medicine, clinical laboratory medicine, anesthesiology, pediatrics, critical care medicine, ultrasound medicine, rehabilitation medicine, general practice, general surgery, and urology.
The hospital is equipped with globally advanced medical technologies, including the CyberKnife system and the Da Vinci Surgical Robot. It has 1,750 approved hospital beds and a multidisciplinary team of more than 2,800 medical professionals. The hospital records nearly 3.19 million outpatient visits annually and more than 67,000 inpatient discharges each year.
Fosun Foshan Chancheng Hospital has received numerous prestigious recognitions, including:
Global Health Asia-Pacific “Traditional Chinese Medicine Hospital of the Year”
Global Health China “Hospital of the Year”
No. 1 ranking on the GAHA Top 500 Private Hospitals in China list for eight consecutive years
The hospital has also been recognized as:
A National Model Unit for Improved Medical Services
A National Drug Clinical Trial Institution (GCP)
A National Standardized Residency Training Base
Established in 2003, Guangzhou Fosun Chancheng Hospital specializes in cardiovascular medicine, oncology, and neurosciences. The hospital has established a National Chest Pain Center, Stroke Center, Trauma Center, and MDT Center, supporting the development of emergency medicine, obstetrics and gynecology, intensive care, anesthesiology, gastroenterology, general surgery, urology, and general practice.
The hospital operates more than 800 inpatient beds and 48 clinical and medical technology departments, supported by a team of over 880 healthcare professionals.
Guangzhou Fosun Chancheng Hospital has received several honors and industry recognitions, including:
EMBA Innovation Practice Base
Guangdong Private Medical Reform & Innovation Brand
Guangdong Private Medical Industry Pioneer Brand
Outstanding Brand Hospital for Medical Investment Contribution
Upload your colposcopy and pathology reports, pelvic MRI images, PET CT, and NGS results (PD-L1, HER2, MSI, etc.). Our multidisciplinary cervical cancer team will provide a personalized treatment plan—including fertility preservation assessment and interventional downstaging strategy—within 48 hours.
